These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 17187139)

  • 41. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A--Dysport and Botox--assuming a ratio of 4:1.
    Sampaio C; Ferreira JJ; Simões F; Rosas MJ; Magalhães M; Correia AP; Bastos-Lima A; Martins R; Castro-Caldas A
    Mov Disord; 1997 Nov; 12(6):1013-8. PubMed ID: 9399229
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Botulinum toxin treatment of hemifacial spasm and blepharospasm: objective response evaluation.
    Thussu A; Barman CR; Prabhakar S
    Neurol India; 1999 Sep; 47(3):206-9. PubMed ID: 10514580
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Changes in dose and injection pattern in the botulinum toxin long-term therapy of facial dyskinesis].
    Laskawi R; Niemczewska A; Schneider S; Winterhoff J; Beutner C; Rohrbach S
    Laryngorhinootologie; 2014 Mar; 93(3):186-92. PubMed ID: 24323508
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Long-term treatment with botulinum toxin: dosage, treatment schedules and costs].
    Schnider P; Birner P; Moraru E; Auff E
    Wien Klin Wochenschr; 1999 Jan; 111(2):59-65. PubMed ID: 10081123
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term stable efficacy of botulinum toxin A in facial movement disorders with no need for increasing dose.
    Badarny S; Ibrahim R; Susel Z; Zaina A; Nasar R; Badarny Y
    Medicine (Baltimore); 2021 Jun; 100(25):e26481. PubMed ID: 34160460
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Use of botulinum toxin in neuro-ophthalmology.
    O'Day J
    Curr Opin Ophthalmol; 2001 Dec; 12(6):419-22. PubMed ID: 11734681
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outcomes of a regional variant of botulinum toxin type A in the treatment of essential blepharospasm and hemifacial spasms: A retrospective study.
    Maneksha V; Chakrabarty S; Tanwar M; Pillai MR
    Indian J Ophthalmol; 2021 Oct; 69(10):2777-2781. PubMed ID: 34571634
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Botulinum a toxin treatment of hemifacial spasm and blepharospasm.
    Park YC; Lim JK; Lee DK; Yi SD
    J Korean Med Sci; 1993 Oct; 8(5):334-40. PubMed ID: 8305141
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Lacrimal film evaluation of patients with facial dystonia during botulinum toxin type A treatment].
    Costa PG; Cardoso IP; Saraiva FP; Raiza AC; Tanaka LK; Matayoshi S
    Arq Bras Oftalmol; 2006; 69(3):319-22. PubMed ID: 16936952
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The effect of botulinum A toxin repeated injection in treating blepharospasm and hemifacial spasm].
    Wang J; Zhang X
    Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2006 Apr; 20(7):292-4. PubMed ID: 16780139
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term outcome of flexible onabotulinum toxin A treatment in facial dystonia.
    Bladen JC; Feldman I; Favor M; Dizon M; Litwin A; Malhotra R
    Eye (Lond); 2019 Mar; 33(3):349-352. PubMed ID: 30202071
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Low-dose treatment of cervical dystonia, blepharospasm and facial hemispasm with albumin-diluted botulinum toxin type A under EMG guidance. An open label study.
    Rollnik JD; Matzke M; Wohlfarth K; Dengler R; Bigalke H
    Eur Neurol; 2000; 43(1):9-12. PubMed ID: 10601802
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Blepharospasm and Hemifacial Spasm.
    Yen MT
    Int Ophthalmol Clin; 2018; 58(1):1. PubMed ID: 29239872
    [No Abstract]   [Full Text] [Related]  

  • 54. Experience with long-term treatment with albumin-supplemented botulinum toxin type A.
    Mohammadi B; Kollewe K; Wegener M; Bigalke H; Dengler R
    J Neural Transm (Vienna); 2009 Apr; 116(4):437-41. PubMed ID: 19319477
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Blepharospasm and hemifacial spasm. Randomized trial to determine the most appropriate location for botulinum toxin injections.
    Price J; Farish S; Taylor H; O'Day J
    Ophthalmology; 1997 May; 104(5):865-8. PubMed ID: 9160036
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Botulinum toxin for neurological disorders in a movement disorders clinic in Singapore.
    Tan AK
    Singapore Med J; 1998 Sep; 39(9):403-5. PubMed ID: 9885719
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Botulinum toxin A in blepharospasm and hemifacial spasm.
    Behari M; Singh KK; Seshadri S; Prasad K; Ahuja GK
    J Assoc Physicians India; 1994 Mar; 42(3):205-8. PubMed ID: 7860509
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Difference in response to botulinum toxin type A treatment between patients with benign essential blepharospasm and hemifacial spasm.
    Cannon PS; MacKenzie KR; Cook AE; Leatherbarrow B
    Clin Exp Ophthalmol; 2010 Oct; 38(7):688-91. PubMed ID: 20456439
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term efficacy of botulinum a toxin for blepharospasm and hemifacial spasm.
    Gill HS; Kraft SP
    Can J Neurol Sci; 2010 Sep; 37(5):631-6. PubMed ID: 21059510
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term changes in duration of relief with botulinum toxin treatment of essential blepharospasm and hemifacial spasm.
    Ainsworth JR; Kraft SP
    Ophthalmology; 1995 Dec; 102(12):2036-40. PubMed ID: 9098314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.